| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 06/29/2011 | CN101647793B Application of anacardic acid in preparing anti-angiogenic drugs |
| 06/28/2011 | US7968716 Caspase inhibitors and uses thereof |
| 06/28/2011 | US7968596 Preparation and diabetic use of Gibberellins |
| 06/28/2011 | US7968547 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 06/28/2011 | US7968523 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides |
| 06/28/2011 | CA2635196C Glucocorticoid receptor modulators |
| 06/23/2011 | WO2011075462A1 Agent that interacts with serum amyloid a gene for the treatment of glaucoma |
| 06/23/2011 | WO2011075430A1 Methods of inhibiting cataracts and presbyopia |
| 06/23/2011 | WO2011074652A1 Nucleic acid capable of inhibiting expression of hif-2α |
| 06/23/2011 | WO2011073205A1 Combination of carotenoids and epi-lutein |
| 06/23/2011 | WO2011073134A1 Pharmaceutical composition for treatment of dry eye syndrome |
| 06/23/2011 | US20110152797 Prostaglandins and analogues as agents for lowering intraocular pressure |
| 06/23/2011 | US20110152376 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof |
| 06/23/2011 | US20110152359 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising threreof |
| 06/23/2011 | US20110152328 Combination Therapy For Glaucoma |
| 06/23/2011 | US20110152316 3,4-substituted piperidine derivatives as renin inhibitors |
| 06/23/2011 | US20110152313 Synthesis of ageladine a and analogs thereof |
| 06/23/2011 | US20110152307 Ophthalmic composition comprising ascomycin |
| 06/23/2011 | US20110152276 Substituted pyrrolo[2,3-d]pyrimidines as antifolates |
| 06/23/2011 | US20110152274 Preparations and Methods for Ameliorating or Reducing Presbyopia |
| 06/23/2011 | US20110152264 Method and composition for treating ocular hypertension and glaucoma |
| 06/23/2011 | US20110152242 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists |
| 06/23/2011 | US20110152241 Novel compounds as receptor modulators with therapeutic utility |
| 06/23/2011 | US20110152238 Pharmaceutical compounds |
| 06/23/2011 | US20110152236 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 06/23/2011 | US20110152219 Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders |
| 06/23/2011 | US20110152192 Compositions and Methods for the Treatment of Angiogenesis-Related Eye Diseases |
| 06/23/2011 | US20110152171 Histamine binding protein |
| 06/23/2011 | US20110151017 Ophthalmic solutions with improved disinfection profiles |
| 06/23/2011 | US20110150967 Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids |
| 06/23/2011 | US20110150894 Methods of modulating angiogenesis via trpv4 |
| 06/23/2011 | US20110150830 Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents |
| 06/23/2011 | US20110150763 Triazine derivatives and their therapeutical applications |
| 06/23/2011 | CA2781390A1 Bridged bicyclic rho kinase inhibitor compounds, composition and use |
| 06/23/2011 | CA2776860A1 Pharmaceutical composition for treatment of dry eye syndrome |
| 06/22/2011 | EP2336301A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 06/22/2011 | EP2336300A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 06/22/2011 | EP2336299A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 06/22/2011 | EP2336190A2 Anti-VEGF antibodies |
| 06/22/2011 | EP2335735A1 Pharmaceutical composition for treatment of dry eye syndrome |
| 06/22/2011 | EP2335692A1 Silicone liquid and fluorinated liquid for sequential use in the treatment of retinal tears and/or detachments |
| 06/22/2011 | EP2335494A1 Method for concentrating lipid |
| 06/22/2011 | EP2334181A1 Phthalimide derivative metabotropic glutamate r4 ligands |
| 06/22/2011 | EP2054420B1 Benzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof |
| 06/22/2011 | CN1964723B Use of fine grain of macromolecule in preparing transparent tissue visualizing agent |
| 06/22/2011 | CN1903364B Medicine composition containing inhibitor of angiotonase and phenoxy acid compounds |
| 06/22/2011 | CN102105167A Prophylactic or therapeutic agent for axial myopia |
| 06/22/2011 | CN102105133A Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| 06/22/2011 | CN102100904A Reduced glutathione percutaneous absorption preparation and preparation method thereof |
| 06/22/2011 | CN102100891A Preparation technology and production method of new integrative formulation of true warrior decoction |
| 06/22/2011 | CN102100884A Preparation technology of new integrative formulation of minor green-blue dragon decoction |
| 06/22/2011 | CN102100813A Preparation technology of new integrative formulation of poria five powder and production method thereof |
| 06/22/2011 | CN102100802A Chinese medicinal composition for relieving visual fatigue and preparation method thereof |
| 06/22/2011 | CN102100713A Method for preparing water-soluble marigold yellow pigment microcapsules |
| 06/22/2011 | CN102100708A Chinese medicinal preparation for promoting menstrual flow and improving acuity of sight and preparation method thereof |
| 06/22/2011 | CN102100701A Anti-inflammatory and detumescence musk eye drops and preparation method thereof |
| 06/22/2011 | CN102100693A Artificial tears including carnosine and preparation method thereof |
| 06/22/2011 | CN102100675A Ofloxacin otic pill for dogs and cats |
| 06/22/2011 | CN102100665A Eye drops containing vitamin E derivatives and preparation method thereof |
| 06/22/2011 | CN102100664A Injection containing pidotimod potassium salt and preparation method thereof |
| 06/22/2011 | CN102100663A Method for preparing pH sensitive in-situ gel nano slow-release eye drop |
| 06/22/2011 | CN101843662B Chinese medicinal composition for preventing and treating asthenopia |
| 06/22/2011 | CN101708313B Pharmaceutical composition for promoting blood circulation and removing obstruction in channels |
| 06/22/2011 | CN101670030B External medicine for treating suppurative otitis media and preparation method thereof |
| 06/22/2011 | CN101633645B N3 alkylated benzimidazole derivatives as mek inhibitors |
| 06/22/2011 | CN101607077B Traditional Chinese medicine composition for treating vertigo and preparation method thereof |
| 06/22/2011 | CN101596271B Medicament for treating suppurative otitis media and preparation method thereof |
| 06/22/2011 | CN101234136B Medicament for curing diabetes retina affection |
| 06/22/2011 | CN101194980B Powder medicament for treating otitis media suppurative |
| 06/22/2011 | CN101167787B Albizzia plant extraction composition for inhibiting angiogenesis and preparation and application thereof |
| 06/21/2011 | US7964646 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| 06/21/2011 | US7964557 Administering adiponectin; inhibitory effect of adiponectin on choroidal angiogenesis or choroidal neovascularization |
| 06/21/2011 | US7964199 Therapeutic composition comprising a botulinum neurotoxin |
| 06/21/2011 | CA2635412C Agent for prophylaxis and treatment of asthenopia or pseudomyopia |
| 06/21/2011 | CA2474192C Nicotinamide derivates useful as p38 inhibitors |
| 06/21/2011 | CA2472341C Phosphorus-containing compounds & uses thereof |
| 06/21/2011 | CA2472188C Polymeric gel system for the controlled delivery of codrugs |
| 06/21/2011 | CA2370323C Preparation for veterinary use for the prevention of ear diseases |
| 06/21/2011 | CA2359115C Acyl derivatives which treat vla-4 related disorders |
| 06/16/2011 | WO2011072091A1 Methods and compositions for treating diseases, disorders or injury of the cns |
| 06/16/2011 | WO2011071995A2 Compounds and methods of treating ocular disorders |
| 06/16/2011 | WO2011071970A2 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
| 06/16/2011 | WO2011071916A2 Sr-bi as a predictor of human female infertility and responsiveness to treatment |
| 06/16/2011 | WO2011071620A1 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
| 06/16/2011 | WO2011071135A1 Oxazine derivative |
| 06/16/2011 | WO2011071095A1 Benzamide compound |
| 06/16/2011 | WO2011070781A1 Substituted aminothiazine derivative |
| 06/16/2011 | WO2011019940A3 Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method for use |
| 06/16/2011 | WO2011014587A3 Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| 06/16/2011 | US20110144562 Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields |
| 06/16/2011 | US20110144330 2,4-Pyrimidinediamine Compounds and their Uses |
| 06/16/2011 | US20110144309 Manipulation of Cytokine Levels Using CD83 Gene Products |
| 06/16/2011 | US20110144200 Combination of carotenoids and epi-lutein |
| 06/16/2011 | US20110144197 Alcanoic acid amides substituted by saturated o-heterocycles |
| 06/16/2011 | US20110144150 Bridged bicyclic rho kinase inhibitor compounds, composition and use |
| 06/16/2011 | US20110144133 Substituted pyrimidone derivatives |
| 06/16/2011 | US20110144132 Substituted pyrimidin-4-one derivatives |
| 06/16/2011 | US20110144127 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 06/16/2011 | US20110144122 Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same |
| 06/16/2011 | US20110144101 Macrocyclic compounds useful as pharmaceuticals |